DIECI, Maria Vittoria
 Distribuzione geografica
Continente #
NA - Nord America 3.151
EU - Europa 1.623
AS - Asia 793
SA - Sud America 34
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 5.622
Nazione #
US - Stati Uniti d'America 3.133
IE - Irlanda 334
GB - Regno Unito 330
IT - Italia 316
CN - Cina 225
SG - Singapore 207
SE - Svezia 186
HK - Hong Kong 173
DE - Germania 145
RU - Federazione Russa 82
UA - Ucraina 67
FI - Finlandia 48
ID - Indonesia 44
TR - Turchia 40
IN - India 37
BG - Bulgaria 31
FR - Francia 24
BR - Brasile 22
CA - Canada 18
VN - Vietnam 16
KR - Corea 12
TW - Taiwan 12
NL - Olanda 10
CZ - Repubblica Ceca 8
LT - Lituania 8
ES - Italia 6
IR - Iran 6
AT - Austria 4
AU - Australia 4
BE - Belgio 4
EG - Egitto 4
PL - Polonia 4
BO - Bolivia 3
CO - Colombia 3
EU - Europa 3
GR - Grecia 3
JP - Giappone 3
MY - Malesia 3
PK - Pakistan 3
RO - Romania 3
VE - Venezuela 3
BH - Bahrain 2
CH - Svizzera 2
CL - Cile 2
DK - Danimarca 2
IQ - Iraq 2
KE - Kenya 2
LY - Libia 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
AR - Argentina 1
BJ - Benin 1
HU - Ungheria 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
ME - Montenegro 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 5.622
Città #
Santa Clara 475
Fairfield 391
Dublin 334
Ashburn 241
Woodbridge 234
Southend 229
Chandler 219
Houston 175
Seattle 173
Hong Kong 170
Singapore 146
Ann Arbor 135
Cambridge 134
Dearborn 132
Wilmington 118
Jacksonville 114
Nyköping 113
Beijing 57
Modena 46
Jakarta 44
San Diego 42
Moscow 38
Princeton 34
Helsinki 31
Sofia 31
New York 28
Shanghai 26
Eugene 25
Izmir 22
Milan 21
London 19
Falls Church 18
Bologna 16
Des Moines 15
Dong Ket 15
Norwalk 15
Redwood City 15
Rome 13
Bremen 12
Guangzhou 12
Turin 12
Council Bluffs 11
Naples 11
Ottawa 11
Fremont 10
Los Angeles 10
Munich 10
Nuremberg 10
Padova 9
Mumbai 8
Nanjing 8
Taipei 8
Catania 7
Boardman 6
Florence 6
Gelsenkirchen 6
Wuhan 6
Brno 5
Chicago 5
Hyderabad 5
Kilburn 5
Kunming 5
Toronto 5
Amsterdam 4
Bagnacavallo 4
Bangalore 4
Dortmund 4
Duncan 4
Frankfurt am Main 4
Genoa 4
Nanchang 4
Parma 4
Phoenix 4
San Mateo 4
Shenyang 4
Boston 3
Fulham 3
Gurgaon 3
Hangzhou 3
Hefei 3
Jungnang-gu 3
La Paz 3
Legnaro 3
New Bedfont 3
Palermo 3
Santiago de Cali 3
Sassuolo 3
Seoul 3
Trento 3
Wandsworth 3
Assago 2
Augusta 2
Berlin 2
Brussels 2
Calimera 2
Casalgrande 2
Cesena 2
Chania 2
Dallas 2
Falkenstein 2
Totale 4.420
Nome #
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 309
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 261
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 247
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 241
Immune characterization of breast cancer metastases: prognostic implications. 217
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 211
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 209
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 204
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 200
Timing for starting second line therapy in recurrent ovarian cancer. 200
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 199
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 194
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 193
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 177
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 174
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 164
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 159
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 153
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 149
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 139
Tumori ginecologici 137
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 134
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 131
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 126
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 124
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. 113
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 113
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 111
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT 99
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 86
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). 75
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 74
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials 56
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 53
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 53
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 52
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 50
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) 46
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â € "Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 31
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 22
Pregnancy after Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study 6
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers 5
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 3
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study 3
Totale 5.703
Categoria #
all - tutte 24.442
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.442


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020278 0 0 0 0 0 0 0 78 73 33 63 31
2020/2021962 70 34 69 63 82 109 97 104 66 120 101 47
2021/2022630 29 73 77 19 25 35 32 33 66 60 120 61
2022/2023961 74 97 43 53 63 97 16 60 399 7 25 27
2023/2024572 24 24 30 27 77 39 69 118 25 23 39 77
2024/20251.122 54 27 30 139 360 313 138 61 0 0 0 0
Totale 5.703